SQI Diagnostics Amends Purchase Deal of Scienion to Push Back Termination Date | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced it has amended its deal to buy Scienion in order to push back the date by which the deal can be terminated.

The termination date is now Oct. 5, changed from the original date of Sept. 30. No reason was given for the change. SQI also has agreed to issue an additional 173,797 common shares of its stock to Scienion in consideration of the extension, the Toronto-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.